Literature DB >> 26652280

A discussion on adult mesenchymal stem cells for drug delivery: pros and cons.

Lauren S Sherman1,2, Alexandra Condé-Green1,3, Oleta A Sandiford2, Pranela Rameshwar1,2.   

Abstract

Mesenchymal stem cells (MSCs) are emerging as candidates for drug delivery to treat numerous diseases. Their ease of isolation, expansion and reduced ethical concern, coupled with their 'plastic' immune functions and homing abilities make MSCs an appealing choice as cellular vehicle for drug delivery, including the delivery of RNA. However, while MSCs are currently listed for thousands of clinical trials, there are many confounding factors that have yet to be elucidated. In this review, we address many of the benefits of MSCs as therapeutic agents, and discuss confounding factors that require further scientific exploration.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26652280     DOI: 10.4155/tde.15.80

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  3 in total

Review 1.  Immune Regulation of Tissue Repair and Regeneration via miRNAs-New Therapeutic Target.

Authors:  Celeste Piotto; Ziad Julier; Mikaël M Martino
Journal:  Front Bioeng Biotechnol       Date:  2018-07-13

2.  Erythropoietin-Modified Mesenchymal Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis Model.

Authors:  Xianyao Wang; Huizhen Wang; Junhou Lu; Zhanhui Feng; Zhongshan Liu; Hailiang Song; Heng Wang; Yanhua Zhou; Jianwei Xu
Journal:  Tissue Eng Regen Med       Date:  2020-07-03       Impact factor: 4.169

3.  Mesenchymal stem cells, implications for pain therapy.

Authors:  Elena Trallori; Carla Ghelardini; Lorenzo Di Cesare Mannelli
Journal:  Neural Regen Res       Date:  2019-11       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.